Associated Papers
In silico modeling guides identification of novel JAK1 variants associated with immune dysregulation.
Jeanpierre M et al.
Embo Molecular Medicine, 2025
41136770 (PubMed )
Supplement: 44321_2025_317_MOESM3_ESM.xlsx › Sheet1
Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M et al.
Nature, 2024
38383791 (PubMed )
Supplement: 41586_2024_7103_MOESM3_ESM.xlsx › Sup_Table_4
Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.
Pilati C et al.
Cytokine & Growth Factor Reviews, 2015
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.
Pilati C et al.
Cancer Cell, 2014
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T et al.
Haematologica, 2011
Select a paper to view details